Finance entity
Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention Aardvark Therapeutics, the most common co-covered peer. Their average consequence score of 5 runs below the beat's 6.3 for that window.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention Aardvark Therapeutics, the most common co-covered peer. Their average consequence score of 5 runs below the beat's 6.3 for that window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. Ascendis Pharma appears in 1 tracked Finance story from March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 95 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ascendis Pharma. Shared-story counts are live from our verified record — not editorial picks.
The biotech sector experienced a week of high-stakes regulatory and clinical developments, headlined by a key FDA approval for Ascendis Pharma. Meanwhile, Aardvark Therapeutics faced a setback with its HERO trial on hold, and Theravance Biopharma announced strategic job cuts to preserve capital.
Ascendis Pharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
